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Background: Recent discoveries have indicated that, in the developing heart, sinus venosus and 
endocardium provide major sources of endothelium for coronary vessel growth that supports the 
expanding myocardium. Here we set out to study the origin of the coronary vessels that develop 
in response to vascular endothelial growth factor B (VEGF-B) in the heart and the effect of 
VEGF-B on recovery from myocardial infarction.  
Methods: We used mice and rats expressing a VEGF-B transgene, VEGF-B-gene-deleted mice 
and rats, Apelin (Apln)-CreERT2 and Npr3-CreERT2 recombinase-mediated genetic cell lineage 
tracing and viral vector-mediated VEGF-B gene transfer in adult mice. Left anterior descending 
coronary vessel ligation was performed and EdU-mediated proliferating cell cycle labeling, flow 
cytometry, histological, immunohistochemical, and biochemical methods, single-cell RNA 
sequencing and subsequent bioinformatic analysis, micro-computed tomography, and fluorescent 
and tracer-mediated vascular perfusion imaging analyses were used to study the development 
and function of the VEGF-B-induced vessels in the heart.  
Results: We show that cardiomyocyte overexpression of VEGF-B in mice and rats during 
development promotes the growth of novel vessels that originate directly from the cardiac 
ventricles and maintain connection with the coronary vessels in subendocardial myocardium. In 
adult mice, endothelial proliferation induced by VEGF-B gene transfer was located 
predominantly in the subendocardial coronary vessels. Furthermore, VEGF-B gene transduction 
prior to or concomitantly with ligation of the left anterior descending coronary artery promoted 
endocardium-derived vessel development into the myocardium and improved cardiac tissue 
remodeling and cardiac function. 
Conclusions: The myocardial VEGF-B transgene promotes the formation of endocardium-
derived coronary vessels during development, endothelial proliferation in subendocardial 
myocardium in adult mice, and structural and functional rescue of cardiac tissue after myocardial 
infarction. VEGF-B could provide a new therapeutic strategy for cardiac neovascularization after 
coronary occlusion to rescue the most vulnerable myocardial tissue. 
 
Key Words: VEGF, revascularization, myocardial ischemia, cardiac protection, gene therapy. 
 
Non-standard Abbreviations and Acronyms  
AAV - adeno-associated viral vector 
αMHC - α-myosin heavy chain 
Apln - apelin 
CMC - cardiomyocyte 
CVD - cardiovascular diseases 
DALY - disability-adjusted life years  
DiI - 1,1-dioctadecyl-3,3,3,3-tetramethylindocarbocyanine perchlorate 
EC - endothelial cell 
5-ethynyl-2’-deoxyuridine - EdU  
EF - ejection fraction 
i.p. - intraperitoneal 
LAD - left anterior descending 
MI - myocardial infarction  










microCT - micro computed tomography 
PFA - paraformaldehyde 
PlGF - placenta growth factor 
RT - room temperature 
SV- sinus venosus 
scRNA - single-cell RNA 
TG - transgene 
UMAP - uniform manifold approximation and projection 
VEGF - vascular endothelial growth factor A 
VEGF-B - vascular endothelial growth factor B 
VEGFR-1 - vascular endothelial growth factor receptor 1 
 
Clinical Perspective  
 
What is new? 
• VEGF-B promotes coronary vessel development from ventricular endocardium to 
subendocardial myocardium, and improves reperfusion and cardiac function after 
myocardial infarction.  
• In ischemic heart disease, this could provide a new possibility to improve cardiac 
perfusion. 
What are the clinical implications? 
• Regardless of rapid reperfusion of the ischemic or infarcted heart, insufficient 
subendocardial vessel perfusion (“no-flow reperfusion”) occurs frequently and diffuse 
coronary artery disease is not amenable to revascularization by percutaneous 
interventions. 
• We show that during heart development, the myocardial VEGF-B transgene promotes the 
formation of endocardium-derived coronary vessels, and after myocardial infarction, 
VEGF-B provides structural and functional rescue of cardiac tissue.  
• The ability of VEGF-B to stimulate de novo vessel growth from the ventricles into the 
myocardium could form a basis for development of new therapeutic strategies for cardiac 














Cardiovascular diseases (CVDs) currently form the single most important class of non-
communicable diseases and a leading cause of mortality in the western world. CVDs also rank 
first when scored according to disability-adjusted life years (DALY) criteria1. Coronary heart 
disease is the number one cause of death among the CVDs2. The subendocardial region is 
vulnerable to ischemia and infarction especially in hypertensive patients because it is the most 
distant target of coronary perfusion, which occurs mainly during the diastolic phase of the 
cardiac contraction cycle3. Currently, the treatment of coronary occlusion is mainly catheter-
assisted reperfusion and thrombolysis of the coronary vessels. A timely reperfusion of the 
myocardium is critical, as adult cardiomyocytes (CMCs) are limited in their capacity to 
regenerate4. However, regardless of the reperfusion, insufficient subendocardial blood flow (“no-
flow reperfusion”) occurs frequently5.  
Inspired by studies of blood flow in reptilian hearts and human thebesian veins, attempts 
to induce endogenous angiogenesis were made previously by introducing tissue channels directly 
to the myocardium from the ventricles. Such trials failed, however, to demonstrate clear 
functional benefits or improvement of patient survival6, 7. The discovery that coronary vessels 
develop from the sinus venosus8, endocardium9 and, to a minor extent, from the epicardium10, 11, 
via vasculogenesis, angiogenesis, and arteriogenesis8, has led to the idea that therapeutic 
reperfusion of the myocardium could be reactivated from these sources in adults. Thus far, this 
has not succeeded, however12, 13. 
 Vascular endothelial growth factor (VEGF), which binds to VEGFR-1 and VEGFR-2, is 
the major regulator of developmental and adaptive vascular growth in the heart14. VEGFR-1, 










vasculature development. VEGFR-1 functions mainly as an anti-angiogenic decoy receptor, thus 
its deletion leads to tissue hypervascularization15-19. Despite the fact that VEGF is the strongest 
angiogenic factor of the three VEGFR-1 ligands, its side-effects, such as promotion of vascular 
leakage and leukocyte recruitment, have prevented its use as a proangiogenic factor in the 
treatment of myocardial ischemia20. 
 We have earlier shown that transgenic delivery of VEGF-B into the myocardium in mice 
and rats results in increased coronary vessel size and density and induces a mild non-pathological 
cardiac hypertrophy21, 22. Here, we set out to study the development of a striking coronary vessel 
phenotype occurring in VEGF-B transgenic (TG) mice and rats. We discovered that the VEGF-B 
transgene promotes the endocardial contribution to the coronary vasculature, resulting in 
persistence of ventricle-derived vessels that extend into the subendocardial myocardium. 
Furthermore, we show that endothelial cells (ECs) in the subendocardial vessels respond to 
adeno-associated viral vector (AAV)-mediated VEGF-B delivery by proliferation in the adult 
heart and that, following myocardial infarction (MI), VEGF-B gene transduction can be used to 
rescue a significant proportion of the myocardial damage resulting from the MI .  
 
Methods 
Please refer to the Online-only Data Supplement for an expanded Methods section. Upon 
reasonable request, the data, analytical methods, and the study materials will be made available 
to other researchers for repeating the experimental procedures and reproducing the results. Some 
of the transgenic mouse lines were produced by other researchers and used under the restrictions 











All animal experiments were approved by the animal care committee appointed by the District of 
Southern Finland. Detailed information on the αMHC-VEGFB, Apln-CreERT2, Npr3-CreERT2, 
Rosa26-TdTomatolox/STOP/lox transgenic rodent lines, and experimental procedures and treatments 
used in this study are described in the Online-only Data supplement. The numbers of animals in 
each experiment are provided in the respective figure legends. 
Coronary ligation followed by DiI-perfusion staining 
Coronary ligation was performed in five separate experiments with N=5-6 rats per group. Rat 
hearts were first retrogradely perfused with PBS through the abdominal aorta, followed by 
ligation of the coronaries at the aortic root when the heart was still pumping. Subsequently, we 
infused 40 mmol KCl into the cardiac ventricle to stop the cardiac contraction in diastole and 
then perfused the aorta retrogradely with 1,1-dioctadecyl-3,3,3,3-tetramethylindocarbocyanine 
perchlorate (DiI), using a constant pressure infusion pump at a flow rate of 90 ml/hour, followed 
by 1% paraformaldehyde (PFA), after which the heart was immersed in 4% PFA overnight at 
room temperature (RT).  
Lineage tracing of adult endocardium 
Npr3-CreERT2;R26-tdTomato (6-7 weeks) mice were treated with 3 daily doses of tamoxifen 
through gavage (2 mg/g weight). One week after last tamoxifen treatment, 2 x 1011 AAV-
VEGFB or AAV-Ctrl virus particles were injected intraperitoneally (i.p.) and one week 
thereafter, the LAD was ligated to generate MI. Heart samples were obtained to analyze Npr3-












Cardiac function was analyzed under isoflurane anesthesia before the start and termination of the 
study, by using the Vevo 2100 Ultrasound system. From the short-axis M-mode images, left 
ventricular mass, ejection fraction (EF), fractional shortening (FS), interventricular septum width 
(diastolic and systolic), left ventricular internal diameter (diastolic and systolic), left ventricular 
posterior wall width (diastolic and systolic), and left ventricular volume (diastolic and systolic) 
were calculated. Please also see the Supplemental Table 1 and 2 for the echocardiographic 
measurements. 
MicroangioCT 
Four-month-old αMHC-VEGF-B mice and rats and their wild-type littermates were anesthetized, 
heparinized, and the thoracic aorta was cannulated in retrograde direction. After washing the 
blood out with warm heparin (10U/ml)-PBS solution, the mice were perfused with microAngiofil 
(perfusion speed 0.5 ml/min, for at least 2 ml) and left at room temperature for microAngiofil 
polymerization for at least 30 minutes, as described earlier11. The hearts were covered with wet 
tissue during that time to prevent sample drying. Thereafter, the hearts were harvested and 
immersion-fixed in PFA 4% until further processing. At a later time-point, the specimens were 
scanned using a microCT desktop scanner Skyscan 1272 (Bruker microCT, Belgium) with the 
following scanning parameters: accelerating voltage 100kV, Cupper filter (0.11mm), isotropic 
voxel size=(2.7µm)3, rotation step 0.1 degrees, 360-degrees scan, frame averaging=ON. The 
reconstructions represent virtual sections across the obtained dataset. The white color 












The data sets from individual experiments were first tested with Kolmogorov–Smirnov normality 
tests and were then analyzed with either 2-way ANOVA with a Holm-Sidak post hoc test or a 2-
tailed Student’s t test. P<0.05 was considered statistically significant. The data are presented as 
mean±SEM. GraphPad Prism 7 software was used for the statistical analyses. 
 
Results 
VEGF-B transgene promotes growth of cardiac vasculature and mass postnatally. Adult 
αMHC-VEGF-B mice expressing the VEGF-B transgene in CMCs showed increased coronary 
vasculature, heart weight/bodyweight ratio and CMC size21, but no increase in the common 
pathological cardiac markers (Fig. 1A,C). The αMHC-VEGF-B embryos developed normally 
and were born in Mendelian ratios (Fig. 1D). Their coronary vessel areas and heart weight/body 
weight ratios were found to be significantly increased from postnatal day 7 onwards when 
compared to those of the wild type (WT) mice (P7) (Fig. 1E,F).  
Cardiac vessels in VEGF-B transgenic mice and rats are perfused directly from the 
ventricles 
In our earlier study, we found enhanced arterialization of vessels in the hearts of the αMHC-
VEGF-B rats21. To further study the cardiac vasculature and its development in the TG vs. WT 
rats, we first performed high-resolution microCT imaging using microAngiofil. This revealed 
myocardial vessels that originated from the ventricular endocardium in the TG hearts, whereas in 
the WT hearts, such vessels were not present (Fig. 2A). This was interesting, because normally 
after coronary development, a subendocardial connective tissue layer forms that prevents further 










vessels originating from the ventricles can deliver blood to the coronary vessels, we ligated, in 
both the TG and WT rats, all coronaries at the aortic root and then perfused the ventricles 
retrogradely via the aorta with the lipophilic DiI carbocyanine dye that incorporates into EC 
membranes24 (Fig. 2 B-D, Figure I in the Supplement). Analysis of thick longitudinal sections 
of the hearts showed prominent DiI staining in the subendocardial vessels and in some vessels 
across the myocardium in the TG hearts, but not in the WT hearts (Fig. 2B-D, Figure II in the 
Supplement). To compare the DiI-positive and negative vessels, we additionally stained the 
sections with DyLight488-labeled Lycopersicon esculentum lectin as an endothelial marker. We 
found that the DiI-positive vessels in the TG mice were connected to the rest of the coronary 
vasculature as an integral part of the functional coronary vascular tree (Fig. 2D, Figure I in the 
Supplement). These results indicated that the VEGF-B transgene is capable of promoting 
development of the subendocardial coronary vasculature that arises de novo from the 
endocardium9, 25. 
AAV-VEGF-B induced gene expression and proliferation in cardiac ECs 
In order to study the protective function of VEGF-B delivered to the adult heart, we first tested 
adeno-associated viral vector (AAV) mediated gene transduction of CMCs. Using AAV-EGFP, 
expressing the green fluorescent protein and flow cytometry, we first confirmed that the AAV 
vector transduces the CMCs efficiently. We then also confirmed that the ECs in the AAV-
VEGF-B transduced hearts expressed only the endogenous VEGF-B gene (Figure III in the 
Supplement). To analyze how VEGF-B gene delivery modulates the endothelial transcriptome 
in the adult heart, we performed single-cell RNA sequencing of the cardiac ECs two weeks after 
AAV-VEGF-B-transduction. For the EC isolation strategy, see Figure IV in the Supplement. In 










highly proliferating ECs (Fig. 3A-C, Figure V in the Supplement A-B). The increase in 
capillary ECs in the S and G2/M phases of the cell cycle is illustrated by the scRNA analysis in 
Fig. 3D. Some of the most prominent changes in gene expression in the coronary and in the 
endocardial ECs between the AAV-Ctrl and AAV-VEGF-B transduced samples, such as the cell 
cycle associated transcripts Ccnb2, Birc5 and Top2a, are indicated in the volcano plot analysis 
(Fig. 3E-F). This analysis also confirmed that Pecam1, which normally is expressed less in 
endocardial cells than in coronary vessel ECs, and Nrg1, which is necessary for myocardial 
trabeculation during development26, were upregulated in endocardial ECs from the VEGF-B 
transduced hearts (Fig. 3F). Furthermore, transcripts encoding the endocardium-specific markers 
Cdh11 or Npr3 were higher in the VEGF-B transduced hearts (Fig. 3F). A shift towards 
activated and proliferating ECs was also apparent in the Velocyto analysis of the data27 (Figure 
V in the Supplement C).  
VEGF-B activates ECs throughout the myocardium, but induces proliferation mainly in 
subendocardial ECs 
After intraperitoneal (i.p.) injection of the DNA-integrating proliferation marker 5-ethynyl-2’-
deoxyuridine (EdU), we found about 3-fold more EdU+ EC nuclei in the subendocardium than in 
the subepicardium of the AAV-VEGF-B-transduced hearts, whereas the AAV-Ctrl transduced 
myocardium showed essentially no EdU-labeling (Fig. 4A-B). Interestingly, EdU+ nuclei were 
also observed in the endocardium of the AAV-VEGF-B hearts (Fig. 4B). A similar increase was 
evident in the Ki67+ EC nuclei two weeks after AAV-VEGF-B transduction, but no longer after 
four months (Figure VI in the Supplement). AAV-mediated transduction of the other VEGFR-











AAV-VEGF-B transduction resulted in an increase of cells in the activated EC cluster 5, 
characterized by their increased expression of e.g. apelin (Apln)28 (Figure V in the Supplement 
A). To localize these cells, we injected AAV-VEGF-B or AAV-Ctrl into AplnCreERT2;Td-
tomato reporter mice28. Two weeks after gene transfer, followed by tamoxifen administration, 
the VEGF-B transduced cardiac sections showed two- to three-fold more Apelin+ ECs than did 
the Ctrl samples in both the subepicardium and the subendocardium (Figure VIII in the 
Supplement). These results indicate that, whereas VEGF-B leads to increased EC proliferation 
especially in the subendocardial myocardium, the coronary endothelial activation, evident as 
Apln+ cells, occurred more homogenously in the various parts of the myocardium.  
Cell lineage tracing reveals endocardial contribution to coronary vessels after MI only in 
VEGF-B expressing hearts 
To ask whether the vessels that we observed arise from the endocardium and whether VEGF-B 
can induce endocardial transdifferentiation into coronary vascular endothelium after MI, we 
performed genetic lineage tracing of endocardial cells in the adult heart and analyzed their cell 
fate after MI. We used the Npr3-CreER allele for lineage tracing of the adult endocardium12. We 
injected tamoxifen into Npr3-CreER;R26-Td-Tomato mice, treated the mice with AAV-VEGF-B 
or AAV-Ctrl, and then ligated the left descending coronary artery to induce MI. We then 
analyzed cardiac sections from the mice four weeks after LAD ligation (Fig. 5A). In mice 
without MI, immunostaining for Td-Tomato (red) and the vascular EC marker FABP4 (green) 
showed Td-Tomato fluorescence only in the endocardial cells, but not in the FABP4+ vascular 
ECs (Fig. 5B,C). After MI or a sham operation, almost all endocardial TdTomato+ cells 
remained in the innermost layer of the myocardial wall in the AAV-Ctrl group. In the VEGF-B 










ECs in the myocardium, whereas after MI, a robust increase in the endocardium-derived 
TdTomato+ ECs was observed in the subendocardial vessels of the AAV-VEGF-B transduced 
hearts (Fig. 5D). Statistical analysis showed a significant increase in the vascular endothelial 
contribution from the endocardium in the AAV-VEGF-B vs. AAV-Ctrl group, but only after MI 
(Fig. 5E). Furthermore, lectin perfusion experiments indicated that at least some of the 
endocardium-derived vessels were functional (Fig. 5G, Figure IX in the Supplement). Taken 
together, the genetic lineage tracing results demonstrated that VEGF-B gene delivery before 
LAD ligation is capable of enhancing the endocardial contribution to de novo coronary vessels 
after injury (Fig. 5F). 
VEGF-B gene delivery before or immediately after transient ischemia reduces cardiac area 
at risk and scar tissue after MI 
We then analyzed the functional importance of the timing of VEGF-B gene delivery in relation 
to LAD ligation. Histological and immunohistochemical staining of the myocardial scar tissue 
four weeks after the MI showed smaller scars in the AAV-VEGF-B treated mice than in the 
AAV-Ctrl treated mice (Fig. 6A-B). Due to the difference in the scar size, we also decided to 
assess the unperfused “area at risk” 24 hours after MI, using Evans blue and triphenyltetrazolium 
chloride (TTC) staining, as described earlier29. Similarly to the Masson Trichrome staining, the 
scar area was significantly smaller in the AAV-VEGF-B treated hearts, and the perfused area 
was significantly larger, whereas the area-at-risk was the same. In particular, the subendocardial 
area around the ventricles was perfused in the AAV-VEGF-B treated hearts but not in the AAV-
Ctrl treated hearts (Figure X in the Supplement). This confirmed that the VEGF-B-induced 











VEGF-B increases the number of proliferating cardiac ECs after MI 
To understand the transcriptomic changes that VEGF-B induces in ischemic myocardium, we 
performed scRNA sequencing of ECs from the AAV-VEGF-B and AAV-Ctrl hearts seven days 
after MI (Figure XI and XII in the Supplement). The most significant differences between 
these ECs were detected in the proliferating cell cluster, representing the cell cycle S phase 
(cluster 12) and G2M phase (clusters 10 and 15), which were significantly larger in samples from 
the VEGF-B transduced hearts (Figure XI in the Supplement). Interestingly, Cxcl12, which 
binds to CXCR4, was upregulated in several clusters only in the infarcted VEGF-B transduced 
heart. This may be significant, because a recent study showed that arterial ECs express CXCR4, 
and following injury, capillary ECs increase CXCL12 expression, which leads to arterial 
reassembly and collateralization30. 
VEGF-B gene deletion and gene transfer on heart function after MI 
We next analyzed whether the endogenous VEGF-B gene affects the outcome of LAD ligation. 
Our earlier studies indicated that the expanded coronary vasculature in the VEGF-B TG rats 
protects against MI upon LAD ligation22. However, we found that neither cardiac ejection 
fraction (EF) nor fractional shortening (FS) was altered by VEGF-B gene deletion (Table I in 
the Supplement).  We then tested the functional benefit of AAV-VEGF-B transduction of the 
adult mouse heart six or three days before MI, or immediately following MI. We found that 
AAV-VEGF-B transduction, measured two weeks after MI, improved EF and FS (Fig. 6C, 
Table II in the Supplement). An improved EF was also evident in AAV-VEGF-B transduced 
hearts two weeks after a 45-minute ischemia-reperfusion treatment (Figure XIII in the 










mice also retained significantly thicker myocardial walls than did the AAV-Ctrl mice (Table II 
in the Supplement).  
 
Discussion 
Here we present the striking observation that myocardial expression of the VEGF-B transgene 
leads to persistence of cardiac vessels derived from the endocardium that perfuse the 
subendocardial myocardium. Furthermore, in adult mice, the delivery of a VEGF-B transgene 
led to proliferation of coronary ECs particularly in the subendocardial myocardium. Myocardial 
VEGF-B gene transduction, occurring prior to or immediately after LAD ligation, promoted 
transdifferentiation of endocardial cells into vascular ECs and their participation in the growth of 
the coronary vasculature, as well as improved cardiac function after MI. These results suggest 
that during the myocardial remodeling process after MI, VEGF-B can reactivate the endocardial 
contribution to coronary vessel formation. This means that, in ischemic heart disease, VEGF-B 
has the potential of augmenting the development of endocardium-derived cardiac 
neovascularization. 
 During mouse development, endogenous VEGF-B expression starts at E10.5 in the 
CMCs of the right ventricle and in the interventricular septum, whereas the atria express much 
less VEGF-B31. During postnatal angiogenesis associated with the massive growth of the 
myocardial wall, VEGF-B expression switches to the LV wall, becoming downregulated after 
postnatal cardiac remodeling to levels observed in the adult heart31. In the αMHC-VEGF-B mice, 
the transgene-encoded VEGF-B is secreted by CMCs, which are also the major source of 
endogenous VEGF-B in the WT hearts32. Thus, although the endogenous VEGF-B expression is 










transgene is able to further expand the coronary vasculature during postnatal growth when 
endogenous VEGF expression is elevated.  Importantly, after postnatal development, both the 
vasculature and the cardiomyocyte size were stabilized in the transgenic hearts, thus the relative 
increase in the vasculature and in the CMC cross-sectional area in 2-month-old and 2-year-old 
rats are similar22. 
In the developing heart, the sinus venosus (SV)8 and the endocardium provide the major 
sources of coronary vessels9, 25, which grow in three major waves to support the expanding 
myocardium during gestation and neonatally33. The majority of the coronary vessels in the 
ventricular free wall originate from the SV endocardium, whereas interventricular septal vessels 
develop from the ventricular endocardium10. In the adult heart, the extent of endocardial 
contribution to the formation of coronary ECs after an injury, such as MI, is minimal, although it 
may depend on the extent of hypoxic damage34, 35. The increased subendocardial vascularization 
that we found in the hearts expressing the VEGF-B transgene is important, as the subendocardial 
myocardium is particularly vulnerable to myocardial infarction36. Research in the field has 
suggested that a lower blood supply to the subendocardium and higher compliance of the 
subendocardial vessels leads, in cardiac ischemia, to the subendocardial vulnerability3.  
 During the cardiac development of vertebrates, the trabecular myocardium undergoes 
compaction regulated by paracrine signals between the endocardium and the myocardium13. The 
Notch and Neuregulin pathways are essential for this process, which starts before the heart tube 
assembly at E8.026. In mouse cardiac development, the endocardium-to-vessel transition occurs 
during trabecular compaction morphogenesis26, 37. In this process, the endocardial cells that are 
trapped between the compacting myocardial trabeculae undergo a phenotypic transition to 










thus forms the origin of subendocardial vessels that anastomose with coronary vessels derived 
from the SV and become perfused. Interestingly, this process of endocardial “touchdown” 
formation, in which endocardial cell ridges encapsulate the trabecular myocardium and start to 
form the initial trabecular architectural units, corresponds to the angiogenic sprouting in other 
vascular beds38.  
 Vessels that emerge from the cardiac ventricles occur in mammals and in lower species, 
in which they are believed, on the one hand, to provide a myocardial drainage route, and on the 
other hand, to nourish the myocardium with oxygenated blood39. Such venous connections are 
called “Thebesian veins”, and arterialized vessels called vessels of Wearn40, 41. In humans, the 
number of such vessels is normally between 0 and 10, and in unchallenged conditions their role 
thus seems insignificant39. In non-mammalian species, however, these vessels play a role in 
perfusing the intertrabecular region, with their anastomoses to the coronary vasculature40.  
 Even though adult endocardial cells contribute only minimally to cardiac ECs after 
injury, endocardial cells that become entrapped in the myocardium during post-ischemic 
remodeling may contribute to the vessel growth in the damaged myocardial tissue12. Thus, 
endocardial tissue remodeling could offer a source for cardiac neovascularization in pathological 
conditions. This idea is consistent with our present results, showing that in the adult heart, the 
tissue remodeling after MI was required for the VEGF-B-induced endocardial-to-vascular 
endothelial contribution in the regenerating vessels. However, whereas the endogenous program 
makes none at all or only a minimal contribution to the coronary circulation42, our results 
indicate that VEGF-B is the first factor found that can induce both vessel growth and endocardial 










endocardial ECs transdifferentiate into vascular ECs and participate in de novo coronary vessel 
formation.  
 Because the reperfusion of the subendocardial region of the heart is a major problem, we 
examined AAV-gene therapy as a safe and feasible method to deliver VEGF-B for the 
stimulation of cardiac subendocardial vessel growth. Upon VEGF-B transduction, we found a 
clear increase in proliferating ECs, located mostly in the subendocardial region. This is most 
likely due to angiogenesis stimulated indirectly by VEGF-B via VEGF-VEGFR-2 signaling, 
which is in agreement with the increased vasculature density previously observed in AAV-
VEGF-B-transduced hearts21. Moreover, VEGF-B167 protein, delivered via a slow release 
minipump has enhanced revascularization of the myocardial border zone after infarction caused 
by LAD-ligation43. A cardiomyocyte‐specific VEGF‐B transgene was also associated with 
reprogramming of CMC metabolism and preservation of mitochondrial complex I function upon 
ischemia‐reperfusion22. In dogs subjected to tachypacing-induced cardiomyopathy, VEGF-B167 
markedly preserved diastolic and contractile function and attenuated ventricular chamber 
remodeling, halting the progression from compensated to decompensated heart failure44. These 
studies suggest that VEGF-B has therapeutic effects in regard to myocardial ischemia and heart 
failure. 
 VEGF-B expression was reported to decline in heart failure patients, where circulating 
VEGF-B levels are inversely correlated with ongoing left ventricular remodeling45, 46. We 
considered that myocardial delivery of VEGF-B could be therapeutic in cardiac remodeling after 
acute ischemia/injury, when the subendocardium reverts transiently to its former 
hypertrabeculated state, which may facilitate endocardium-derived neovascularization35, 47. We 










VEGFR-2, which transduces the VEGF-B-mediated angiogenic signals, is upregulated after MI 
also in endocardial flower-shaped structures that contain proliferating ECs47. In agreement with 
our hypothesis, AAV-VEGF-B transduction six days before the MI prevented the decrease of 
cardiac EF. Surprisingly, a protective effect on the cardiac function was observed even when 
AAV-VEGF-B was injected three days before, or even just after the LAD ligation, indicating for 
the first time that the coronary endothelial growth promoted by VEGF-B gene delivery is 
beneficial during acute cardiac injury. These results suggest that VEGF-B gene delivery could be 
useful in inoperable acute coronary syndrome patients or in combination with balloon 
angioplasty to overcome the often-occurring no-reflow phenomenon.  
 VEGF-B thus fulfills many of the desired features for a vascular perfusion-enhancing 
agent. It has been shown to protect from microvascular defects generated during cardiac stress, 
an important aspect for avoidance of the no-flow phenomenon and successful reperfusion22. It 
also promotes vessel arterialization21, which is crucial for pressurized blood delivery into the 
cardiac muscle. Furthermore, a clear advantage of VEGF-B in comparison with other angiogenic 
factors is that it cannot be overdosed. This is because an excess of VEGF-B works merely by 
binding to the VEGFR-1 decoy receptor, thereby displacing the endogenous VEGF for induction 
of angiogenesis through the VEGFR-2-signaling pathway, which in turn promotes mild CMC 
growth through paracrine EC-CMC crosstalk48. It is important to note, that the therapeutic dosing 
window is much smaller for VEGF-A than for VEGF-B, because VEGF-A is poorly angiogenic 
in the heart49, and its side effects, such as vascular leakage and inflammation are greater, which 
thus far has compromised its use in the treatment of cardiovascular ischemic conditions 21, 22, 50.  
 In conclusion, we present a novel VEGF-B function in the endocardial 










blood vessels in the heart. Our study shows that VEGF-B is capable of reactivating an organ-
specific developmental growth program that is distinct from angiogenic sprouting in other 
developing vascular beds, thus overcoming the insufficiency of intrinsic developmental 
mechanisms that drive new vessel formation in the injured heart (Figure XIV in the 
Supplement).  Studies of the endocardial transcriptome and possible progenitor-like EC clusters 
are required to find out how VEGF-B alters the endocardial cells during development and repair 
of the coronary vessels and how it can be further boosted for an improved functional and 
eventually therapeutic benefit. This is a translationally and clinically relevant research area, 
which could provide a new possibility for the development of better myocardial perfusion to the 
injured heart directly from the cardiac ventricles. 
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Figure 1. Cardiac phenotype and its development in the αMHC-VEGF-B TG mice. (A) 
Macroscopic images of the hearts and ANP and BNP RNA levels at 4 months (B) IF staining of 
cardiac sections for myocytes (dystrophin-2) and blood vessels (CD31) (C) Quantification of 
cardiomyocyte size (μm²) and blood vessel area. (D) Percentage of TG embryos, pups, and adults 
at the indicated time points (E) Blood vessel area fraction. (F) Heart weight normalized to body 
weight (mg/g) at the indicated embryonic and postnatal days. N=8 per group, mean ± SEM, 
**p<0.01 & *p<0.05. Scale bar= 300 µm. 
 
Figure 2. The ventricle-derived blood vessels in αMHC-VEGF-B TG rats are lumenized 
and connect to coronary blood vessels. (A) MicroCT imaging after retrograde perfusion of the 
ventricles with microAngiofil contrast agent. Arrows indicate blood vessels connected to the 
ventricle. (B) Schematic illustration of the ligation of coronary vessels and quantifications of DiI 
perfused vasculature fraction. (C) DiI staining after coronary ligation and retrograde ventricular 
perfusion of the WT and TG hearts. (D) Immunofluorescent images of DiI and Lycopersicon 
esculentum lectin staining of the subendocardium in the septal region. N=6 rats per group, Scale 
bars: (C) 1 cm (D) 100 µm, LCA=left coronary artery, RCA=right coronary artery. 
 
Figure 3. Increased expression of transcripts associated with EC activation and 
proliferation in AAV-VEGF-B transduced hearts. (A) UMAP clustering of cardiac ECs from 
AAV-VEGF-B and AAV-Ctrl transduced mice. Cluster 8, which contains hemoglobin transcripts 










proportions of cells in the major EC clusters between the AAV-VEGF-B and AAV-Ctrl 
transduced samples. Note the greater number of proliferating ECs in the VEGF-B transduced 
sample. (C) UMAP plots showing the cell cycle phase of each single cell in both samples. (D) S 
and G2M scores in the samples. (E-F) Volcano plots of genes differentially expressed in ECs (E) 
and endocardial cells (F) between the samples. The threshold is adjusted to a logFC > 0.25 and 
FDR < 0.05. 
 
Figure 4. AAV-VEGF-B promotes EC proliferation predominantly in the subendocardial 
myocardium. (A) Schematic outline of the EdU+Apelin lineage tracing experiment. (B) 
Representative images and quantification of subendocardial and subepicardial %EdU+ 
nuclei/field (N=6 mice/group). Yellow arrowheads point out the EdU+/CD31+ nuclei. Mean +/- 
SEM, ***p<0.0005,  *p<0.05 
 
Figure 5. VEGF-B promotes endocardial contribution to vessel endothelium in the adult 
heart after MI. (A) Schematic figure showing the experimental strategy. (B) Immunostaining of 
Td-Tomato and FABP4 in sections for Npr3-CreER;R26-Td-Tomato TG hearts. (C) 
Quantification of the percentage of Td-Tomato+ cells among endocardial cells and FABP4+ 
coronary endothelial cells. (D) Td-Tomato and FABP4 immunostaining of heart sections after 
MI or sham operation. Note that a subset of endocardial cells contributes to FABP4+ vascular 
endothelial cells (VECs) after AAV-VEGF-B treatment (arrowheads). (E) Quantification of the 
percentage of Td-Tomato+, FABP4+ cells in relation to the infarcted area. (F) Cartoon image 










VE-cadherin on hearts collected 14 days after MI. Mice were perfused with BS lectin before they 
were collected. Mean ± SEM, ***p<0.001, **p<0.01. Scale bar: 100 µm. N=5 mice per group. 
Figure 6. VEGF-B gene therapy decreases myocardial scar and improves cardiac ejection 
fraction after MI. (A) Masson Trichrome staining of the hearts and (B) quantification showing 
the scar dimensions when AAV was given 6 days before the MI. (C) cardiac function presented 
as ejection fraction (EF) and left ventricular mass (LV mass) measured from the 
echocardiography two weeks after MI, in 3 separate experiments, in which AAV was given 
either six or three days or right after the LAD ligation (N=6 mice for shams and N=10 mice for 
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